CVS Health to offer lower-cost biosimilar medications starting April 1.

CVS Health announced plans to expand adoption of lower-cost biosimilar medications. Starting April 1, 2026, CVS Caremark will offer osteoporosis biosimilars Ospomyv and Stoboclo, as well as generic teriparatide, Bonsity, and Tymlos on major national commercial template formularies. These medications will replace Prolia and Forteo, providing customers with more affordable options. The preferred biosimilar approach is over 50% lower in costs per prescription than the original brand.